Shares in GSK fell around 9% this morning after ... of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial. Judge Vivian Medinilla of Delaware Superior Court issued an ...
GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
The investors are seeking a jury trial and damages ... Boehringer Ingelheim. In key win for GSK, Delaware court will review decision to allow expert testimony in Zantac cases In 2020, after ...
who did not know that GSK had for decades concealed an internal study that implicated the Company’s liability to Zantac users; and (4) as a result, Defendants’ positive statements about the ...
who did not know that GSK had for decades concealed an internal study that implicated GSK's liability to Zantac users. When the true details entered the market, the lawsuit claims that investors ...
The overhanging Zantac litigation case has dented investor confidence ... It’s a FTSE 100 pharmaceutical flop GSK has posted a string of drug trial wins lately. Its specialty medicines division saw ...
GSK launched Zantac in 1981 and it was first approved for sale in the US in 1983 as a prescription medication. It went on to become the world's best-selling drug, with annual sales in excess of $1bn.
who did not know that GSK had for decades concealed an internal study that implicated the Company’s liability to Zantac users; and (4) as a result, Defendants’ positive statements about the ...
GSK has also settled some Zantac cases before they could go to trial. News of the Pfizer settlement ... The companies got a ...
who did not know that GSK had for decades concealed an internal study that implicated the Company’s liability to Zantac users. When the true details entered the market, the lawsuit claims that ...
who did not know that GSK had for decades concealed an internal study that implicated GSK's liability to Zantac users. When the true details entered the market, the lawsuit claims that investors ...